Certis Blog

Cancer perspectives from Certis Oncology and around the globe. 

AUG 18, 2018: Orthotopic PDX Models with Quantitative Pathology End Points Provide a New Standard in Translational Oncology Drug Development

By: Marisa Keller Orthotopic Patient-Derived Xenografts (PDX) Despite the rise of personalized approaches to the treatment of cancer, translating these therapies into a clinical setting still poses ...

Read more

MAY 18, 2017: A strategic weapon in the fight against recalcitrant cancers.

According to the American Cancer Society’s Cancer Facts & Figures 2017,  there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the US this year. This is ...

Read more